A Phase 1/2 interventional study of CCS1477 and Abiraterone acetate in Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer and Non-small Cell Lung Cancer, sponsored by CellCentric Ltd.. Completed at 19 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by CellCentric Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 757 studies in Breast Neoplasms with a site in United Kingdom — 98 open to participants now, 196 under way, 67 of them phase 3. Breast Neoplasms · United Kingdom.
Among the 757 studies in Breast Neoplasms with a site in United Kingdom, this one is the 309th largest by enrollment of the 613 interventional ones that give a count, is one of 32 that started in 2018, is one of 61 in phase 1/2, and was the 488th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →98 of the 757 studies in Breast Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Zedsen Limited · Sites in United Kingdom
Ages 18–85 · Women only
University Hospitals of North Midlands NHS Trust · Sites in United Kingdom
Ages 18+ · Women only
Imperial College London · Sites in United Kingdom
Ages 16–100
BeOne Medicines · Sites in United Kingdom, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
757 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 125 · Phase 2 238 · Phase 3 229 · Phase 4 7
First in 1987; this study’s year is marked. 32 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 221 across the 613 interventional studies, 221 across the 122 observational. Of the 451 that completed or were terminated, 201 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
422 of 757 have an industry lead sponsor. The 10 most frequent:
CellCentric Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
CellCentric Ltd. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
48 of the studies in Breast Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 48 to your calendar (.ics) → With an account.
Among the 757 studies in Breast Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
The Steering Committee closed selected cohorts, in accordance with its responsibilities, after findings from earlier cohorts indicated that further evaluation of those cohorts was no longer warranted. The remaining cohorts were completed as specified in the protocol. Therefore, the study was considered completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for mCRPC patients only:
Progressive disease documented by one or more of the following:
Additional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:
Additional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:
Additional inclusion criteria for patients in mutation arm:
Exclusion Criteria:
Additional exclusion criteria for patients in CCS1477 plus abiraterone combination arm:
Additional exclusion criteria for patients in CCS1477 plus enzalutamide combination arm:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CCS1477 monotherapy in patients with mCRPC
Drug: CCS1477
CCS1477 monotherapy in patients with mCRPC
Drug: CCS1477
CCS1477 plus abiraterone acetate in patients with mCRPC
Drug: CCS1477 · Drug: Abiraterone acetate
CCS1477 plus enzalutamide in patients with mCRPC
Drug: CCS1477 · Drug: Enzalutamide
CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition
Drug: CCS1477
CCS1477 plus darolutamide in patients with mCRPC
Drug: CCS1477 · Drug: Darolutamide
CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.
Drug: CCS1477 · Drug: Olaparib
CCS1477 plus atezolizumab in patients with non-small cell lung cancer
Drug: CCS1477 · Drug: Atezolizumab
Capsules, oral
Abiraterone acetate 500mg tablets plus prednisone/prednisolone
Enzalutamide 40mg capsules/tablets
300mg tablets
150mg tablets
840mg/14ml concentrate for solution for infusion vials
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Withdrawal
Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study intervention, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs were defined as those events with onset dates/time occurring after study intervention administration or events that worsen after study intervention administration. TEAEs included serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to withdrawal of study intervention was also reported.
Time frame: From signing informed consent until the end of the follow-up period (Up to 363 weeks)
Number of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in hematology according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.
Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Number of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in biochemistry according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.
Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis
The urinalysis measurements included glucose, protein and blood. Number of participants with clinically significant changes from baseline in urinalysis values were reported. Clinically Significance was decided by investigator.
Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
The vital signs measurements included blood pressure, heart rate, respiration rate and temperature. Number of participants with clinically significant changes from baseline in vital signs values were reported. Clinically Significance was decided by investigator.
Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Number of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
Twelve-lead Electrocardiograms (ECGs) were obtained after the participant was in semi-supine for 5 minutes. Three ECGs were taken at each timepoint at about 1-minute intervals. QTcF was calculated using the Fridericia formula: QTcF = QT ÷ RR\^(1/3), where QT is the measured QT interval in milliseconds and RR is the interval between two consecutive R waves on the ECG expressed in seconds. It was categorized as less than equal to (\<=) 450 milliseconds (msec), more than (\>) 450 to \<=480 msec, \> 480 to \<= 500 msec and \> 500 msec.
Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Best percentage change from baseline was defined as the largest percentage reduction in PSA levels or the smallest percentage increase in PSA levels in the absence of a reduction.
Time frame: At Baseline - Cycle 1 - Day 1, Day 8, Day 15, Day 22 and Day 1 of every cycle from cycle 2 onwards until treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Number of Participants With CTC Response
CTC response was defined as a change from unfavourable (five or more cells per 7.5 mL of blood) at baseline to favourable (four or fewer cells per 7.5 mL) post treatment. Number of participants with overall response were reported. A participant was determined as having an overall CTC response if they had at least one post baseline assessment of 'CTC response'.
Time frame: From Baseline - Day 1 Cycle 1 (Predose), Day 1 Cycle 2, Day 1 Cycle 3, Day 1 Cycle 5 up to disease progression or treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Objective response is defined as any participant with measurable disease who has a best overall response of Partial Response (PR) or Complete Response (CR). CR is defined as the disappearance of all Target Lesions (TLs) since baseline. PR is defined as At least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters.
Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Radiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Radiological progression free survival (rPFS) was defined as the time from the start of treatment with CCS1477 in Cycle 1 until the earliest objective disease progression defined by RECIST 1.1, Prostate Cancer Clinical Trial Working Group 3 (PCWG-3) bone progression or death by any cause in the absence of progression, regardless of whether the participants withdraws from study medication or receives another anti-cancer therapy prior to progression. Kaplan - Meier estimate was used to calculate the rPFS.
Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Overall Survival (OS)
Overall survival is defined as the time from the start of treatment with CCS1477 in Cycle 1 until death due to any cause.
Time frame: From start of treatment until death (Up to 363 weeks)
Maximum Observed Plasma Concentration (Cmax)
Cmax was obtained directly from concentration versus time curve.
Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)
AUC0-24 is defined as the area under the concentration-time curve (AUC) from time zero (= dosing time) to 24 hours. AUC0-24 was calculated using the mixed log-linear trapezoidal rule.
Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
The Steering Committee closed selected cohorts, in accordance with its responsibilities, after findings from earlier cohorts indicated that further evaluation of those cohorts was no longer warranted. The remaining cohorts were completed as specified in the protocol. Therefore, the study was considered completed.
| Milestone | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg, BD | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 8 | 4 | 8 | 8 | 6 | 6 | 6 | 4 | 5 | 7 | 5 | 5 | 8 | 2 | 2 | 2 | 15 | 8 | 7 | 7 | 9 | 2 | 3 | 6 | 5 | 4 | 1 | 1 | 6 | 16 | 20 | 4 | 4 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 4 | 8 | 4 | 8 | 8 | 6 | 6 | 6 | 4 | 5 | 7 | 5 | 5 | 8 | 2 | 2 | 2 | 15 | 8 | 7 | 7 | 9 | 2 | 3 | 6 | 5 | 4 | 1 | 1 | 6 | 16 | 20 | 4 | 4 | 7 |
| Withdrew: Abiraterone/enzalutamide responder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 4 | 3 | 8 | 4 | 7 | 8 | 6 | 6 | 5 | 4 | 4 | 6 | 5 | 5 | 6 | 2 | 2 | 2 | 13 | 7 | 6 | 5 | 5 | 1 | 3 | 4 | 4 | 4 | 1 | 1 | 6 | 9 | 11 | 3 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 4 | 3 |
Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study intervention, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs were defined as those events with onset dates/time occurring after study intervention administration or events that worsen after study intervention administration. TEAEs included serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to withdrawal of study intervention was also reported.
| Participants | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 4 | 3 | 8 | 4 | 8 | 7 | 6 | 6 | 6 | 4 | 5 | 7 | 5 | 5 | 2 | 2 | 2 | 23 | 8 | 7 | 6 | 8 | 2 | 3 | 6 | 5 | 4 | 1 | 1 | 6 | 36 | 4 | 4 | 7 |
| SAEs | 4 | 1 | 5 | 3 | 4 | 4 | 1 | 1 | 1 | 2 | 3 | 3 | 0 | 4 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 17 | 1 | 1 | 5 |
| TEAEs leading to withdrawal of CCS1477 | 2 | 0 | 4 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in hematology according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Platelets, Grade 0 to Grade 1 | 24 | 5 | 2 | 11 | 0 | 2 |
| Platelets, Grade 0 to Grade 2 | 4 | 0 | 0 | 2 | 0 | 0 |
| Platelets, Grade 0 to Grade 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Platelets, Grade 0 to Grade 4 | 3 | 0 | 0 | 0 | 0 | 0 |
| Platelets, Grade 1 to Grade 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Platelets, Grade 1 to Grade 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Platelets, Grade 1 to Grade 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils, Grade 0 to Grade 1 | 21 | 3 | 12 | 0 | 3 | 2 |
| Neutrophils, Grade 0 to Grade 1 | 4 | 0 | 0 | 1 | 1 | 0 |
| Neutrophils, Grade 0 to Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Grade 0 to Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Grade 1 to Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 |
Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in biochemistry according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Albumin, Grade 0 to Grade 1 | 12 | 2 | 5 | 7 | 1 | 2 |
| Albumin, Grade 0 to Grade 2 | 10 | 0 | 0 | 3 | 0 | 1 |
| Albumin, Grade 1 to Grade 2 | 0 | 0 | 3 | 1 | 1 | 1 |
| Alkaline Phosphatase, Grade 0 to Grade 1 | 25 | 2 | 7 | 3 | 2 | 1 |
| Alkaline Phosphatase, Grade 0 to Grade 2 | 4 | 1 | 3 | 1 | 0 | 0 |
| Alkaline Phosphatase, Grade 0 to Grade 3 | 1 | 0 | 1 | 0 | 0 | 1 |
| Alanine Aminotransferase, Grade 0 to Grade 1 | 12 | 0 | 0 | 7 | 0 | 2 |
| Alanine Aminotransferase, Grade 0 to Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Aspartate Aminotransferase, Grade 0 to Grade 1 | 25 | 4 | 4 | 11 | 2 | 2 |
| Aspartate Aminotransferase, Grade 0 to Grade 2 | 1 | 0 | 0 | 1 | 0 | 1 |
| Aspartate Aminotransferase, Grade 0 to Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatinine, Grade 0 to Grade 1 | 13 | 2 | 4 | 5 | 1 | 2 |
| Creatinine, Grade 0 to Grade 2 | 18 | 0 | 1 | 3 | 1 | 1 |
| Creatinine, Grade 0 to Grade 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Grade 0 to Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatinine, Grade 1 to Grade 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Grade 2 to Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Lactate Dehydrogenase, Grade 0 to Grade 1 | 35 | 6 | 9 | 9 | 4 | 2 |
| Total Bilirubin, Grade 0 to Grade 1 | 7 | 1 | 4 | 3 | 0 | 1 |
| Total Bilirubin, Grade 0 to Grade 2 | 2 | 0 | 0 | 2 | 0 | 0 |
| Total Bilirubin, Grade 0 to Grade 3 | 2 | 0 | 1 | 0 | 0 | 0 |
| Total Bilirubin, Grade 0 to Grade 4 | 0 | 0 | 0 | 2 | 0 | 0 |
The urinalysis measurements included glucose, protein and blood. Number of participants with clinically significant changes from baseline in urinalysis values were reported. Clinically Significance was decided by investigator.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 |
The vital signs measurements included blood pressure, heart rate, respiration rate and temperature. Number of participants with clinically significant changes from baseline in vital signs values were reported. Clinically Significance was decided by investigator.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 |
Twelve-lead Electrocardiograms (ECGs) were obtained after the participant was in semi-supine for 5 minutes. Three ECGs were taken at each timepoint at about 1-minute intervals. QTcF was calculated using the Fridericia formula: QTcF = QT ÷ RR\^(1/3), where QT is the measured QT interval in milliseconds and RR is the interval between two consecutive R waves on the ECG expressed in seconds. It was categorized as less than equal to (\<=) 450 milliseconds (msec), more than (\>) 450 to \<=480 msec, \> 480 to \<= 500 msec and \> 500 msec.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| <= 450 msec to > 450 - <= 480 msec | 20 | 2 | 9 | 4 | 2 | 2 |
| <= 450 msec to > 480 - <= 500 msec | 1 | 1 | 2 | 1 | 0 | 0 |
| <= 450 msec to > 500 msec | 1 | 0 | 0 | 4 | 0 | 0 |
| > 450 - <= 480 msec to > 480 - <= 500 msec | 1 | 0 | 2 | 0 | 0 | 1 |
| > 450 - <= 480 msec to > 500 msec | 2 | 0 | 2 | 0 | 0 | 0 |
Best percentage change from baseline was defined as the largest percentage reduction in PSA levels or the smallest percentage increase in PSA levels in the absence of a reduction.
| percentage change from baseline | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part F1: CCS1477 in Combination With Darolutamide |
|---|---|---|---|---|
| Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) | 5.39 ± 35.650 | -8.88 ± 39.560 | -2.85 ± 27.712 | -0.89 ± 30.687 |
CTC response was defined as a change from unfavourable (five or more cells per 7.5 mL of blood) at baseline to favourable (four or fewer cells per 7.5 mL) post treatment. Number of participants with overall response were reported. A participant was determined as having an overall CTC response if they had at least one post baseline assessment of 'CTC response'.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy |
|---|---|---|---|---|
| Number of Participants With CTC Response | 6 | 1 | 5 | 0 |
Objective response is defined as any participant with measurable disease who has a best overall response of Partial Response (PR) or Complete Response (CR). CR is defined as the disappearance of all Target Lesions (TLs) since baseline. PR is defined as At least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters.
| Participants | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 1 | 1 | 0 | 0 | 1 | 0 |
Radiological progression free survival (rPFS) was defined as the time from the start of treatment with CCS1477 in Cycle 1 until the earliest objective disease progression defined by RECIST 1.1, Prostate Cancer Clinical Trial Working Group 3 (PCWG-3) bone progression or death by any cause in the absence of progression, regardless of whether the participants withdraws from study medication or receives another anti-cancer therapy prior to progression. Kaplan - Meier estimate was used to calculate the rPFS.
| months | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Radiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 2.8 (1.9 to 3.5) | 1.9 (1.6 to 3.5) | 3.6 (1.9 to 5.5) | 1.9 (1.7 to 2.3) | 2.8 (1.9 to 8.4) | 2.9 (1.7 to NA) |
Overall survival is defined as the time from the start of treatment with CCS1477 in Cycle 1 until death due to any cause.
| months | Part A and B1: CCS1477 Monotherapy | Part C1: CCS1477 in Combination With Abiraterone | Part D1: CCS1477 in Combination With Enzalutamide | Part E1 and E2: CCS1477 Monotherapy | Part F1: CCS1477 in Combination With Darolutamide | Part H1: CCS1477 in Combination With Atezolizumab |
|---|---|---|---|---|---|---|
| Overall Survival (OS) | 10.5 (9.30 to 12.00) | 14.2 (7.80 to 19.50) | 15.4 (10.90 to 17.10) | 10.2 (5.80 to 12.60) | 13.8 (13.70 to NA) | 7.2 (1.80 to NA) |
Cmax was obtained directly from concentration versus time curve.
| nanogram/milliliter(ng/ml) | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 - Day 1 | 708.4 ± 64.0 | 1434.1 ± 104.8 | 823.1 ± 29.3 | 628.5 ± 83.9 | 485.7 ± 66.6 | 375.5 ± 36.9 | 132.1 ± 31.3 | 237.6 ± 65.2 | 303.7 ± 41.5 | 351.4 ± 44.7 | 132.6 ± 68.6 | 968.6 ± 61.7 | 515.4 ± 22.7 | 1462.9 ± 56.2 | 682.9 ± 154.2 | 820.0 ± 56.5 | 893.7 ± 104.4 | 557.5 ± 69.5 | 248.0 ± 104.1 | 522.4 ± 72.5 | 13484.5 ± 68.6 | 14717.1 ± 74.1 | 15440.9 ± 23.6 | 11271.5 ± 97.0 | 15420.6 ± 20.6 | 3449.1 ± 13.2 | 17843.4 ± 6.9 | 259.1 ± 35.4 | 344.3 ± 55.4 | 301.0 ± 102.9 | 427.1 ± 67.5 | 3838.6 ± 16.8 | 6140.8 ± 29.6 | 702.8 ± 55.6 |
| Cycle 2 - Day 3 | — | — | 813 ± NA | — | 676.9 ± 58.5 | — | — | — | 531.5 ± 51.5 | 545.9 ± 51.1 | — | 847.1 ± 55.6 | 670.5 ± 21.0 | 1515.0 ± 46.6 | 1720.0 ± NA | 1160.0 ± NA | — | 633.6 ± 71.6 | — | — | — | 16240.7 ± 4.8 | — | — | 19770.9 ± 32.3 | 16272.2 ± 7.2 | — | — | — | — | — | — | — | — |
AUC0-24 is defined as the area under the concentration-time curve (AUC) from time zero (= dosing time) to 24 hours. AUC0-24 was calculated using the mixed log-linear trapezoidal rule.
| hours*nanograms per milliliter (h*ng/mL) | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 - Day 1 | 5750.4 ± 197.5 | 10447.9 ± 137.3 | 6755.0 ± 47.1 | 5944.7 ± 95.7 | 3790.5 ± 141.8 | 2542.0 ± 59.4 | 829.2 ± 81.8 | 1572.1 ± 88.4 | 1776.1 ± 42.1 | 3697.1 ± 58.3 | 646.4 ± 46.4 | 4195.7 ± 97.2 | 2096.7 ± 32.0 | 6594.1 ± 89.5 | 2873.6 ± 360.0 | 3247.1 ± 0.4 | 3732.8 ± 199.4 | 3299.2 ± 76.9 | 1218.1 ± 93.4 | 2492.1 ± 51.7 | 249370.4 ± 98.4 | 269964.2 ± 99.4 | 292439.6 ± 14.3 | 194471.6 ± 175.9 | 308618.7 ± 20.3 | 38260.0 ± 25.9 | 336943.2 ± 18.1 | 2891.8 ± NA | 3400.8 ± NA | 8460.4 ± 75.6 | 3561.3 ± 114.7 | 1334.9 ± 28.9 | 1852.9 ± 111.7 | 3686.0 ± 48.1 |
| Cycle 2 - Day 3 | — | — | 9543.7 ± NA | — | — | — | — | — | 3103.8 ± 99.1 | 4385.7 ± 36.1 | — | 3582.3 ± 88.2 | 2813.0 ± 19.2 | 8822.0 ± 119.1 | — | — | — | — | — | — | — | 310130.1 ± 24.6 | — | — | 339289.0 ± 37.0 | 296836.3 ± 1.0 | — | — | — | — | — | — | — | — |
Collected over Up to end of study (Up to 363 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: CCS1477 100mg, Once Daily | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) |
| Part A: CCS1477 100mg, 2/Week | 3/4 (75%) | 1/4 (25%) | 3/4 (75%) |
| Part A: CCS1477 100mg, 3 Days on and 4 Days Off | 8/8 (100%) | 5/8 (62.5%) | 8/8 (100%) |
| Part A: CCS1477 100mg, 3/Week | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | 7/8 (87.5%) | 4/8 (50%) | 8/8 (100%) |
| Part A: CCS1477 50mg, Once Daily | 8/8 (100%) | 4/8 (50%) | 7/8 (87.5%) |
| Part A: CCS1477 25mg, BD | 6/6 (100%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A: CCS1477 25 mg, Once Daily | 6/6 (100%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A: CCS1477 50mg, 4 Days on and 3 Days Off | 5/6 (83.3%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A: CCS1477 50mg, 5 Days on and 2 Days Off | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | 6/7 (85.7%) | 3/7 (42.9%) | 7/7 (100%) |
| Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | 5/5 (100%) | 0/5 (0%) | 5/5 (100%) |
| Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Part A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | 6/8 (75%) | 2/8 (25%) | 8/8 (100%) |
| Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Part B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | 13/15 (86.7%) | 4/15 (26.7%) | 15/15 (100%) |
| Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | 7/8 (87.5%) | 5/8 (62.5%) | 8/8 (100%) |
| Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | 6/7 (85.7%) | 3/7 (42.9%) | 7/7 (100%) |
| Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | 5/7 (71.4%) | 1/7 (14.3%) | 7/7 (100%) |
| Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | 5/9 (55.6%) | 1/9 (11.1%) | 8/9 (88.9%) |
| Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | 4/6 (66.7%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | 4/5 (80%) | 1/5 (20%) | 5/5 (100%) |
| Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | 4/4 (100%) | 0/4 (0%) | 4/4 (100%) |
| Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | 6/6 (100%) | 1/6 (16.7%) | 6/6 (100%) |
| Part E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | 9/16 (56.3%) | 7/16 (43.8%) | 15/16 (93.8%) |
| Part E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | 11/20 (55%) | 10/20 (50%) | 20/20 (100%) |
| Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off | 4/7 (57.1%) | 5/7 (71.4%) | 7/7 (100%) |
| Event | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg, BD | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 1/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 0/2 | 1/15 | 0/8 | 0/7 | 0/7 | 1/9 | 0/2 | 2/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 1/16 | 0/20 | 0/4 | 1/4 | 0/7 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 1/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 1/4 | 0/7 |
| ConstipationGastrointestinal disorders | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 1/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| FatigueGeneral disorders and administration site conditions | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 1/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 1/7 |
| Urinary tract infectionInfections and infestations | 0/4 | 0/4 | 1/8 | 0/4 | 1/8 | 0/8 | 0/6 | 0/6 | 1/6 | 1/4 | 2/5 | 1/7 | 0/5 | 1/5 | 0/8 | 1/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| HyponatraemiaMetabolism and nutrition disorders | 2/4 | 0/4 | 1/8 | 0/4 | 1/8 | 1/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| Confusional statePsychiatric disorders | 0/4 | 0/4 | 0/8 | 0/4 | 1/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 1/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 1/20 | 0/4 | 0/4 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 1/4 | 0/4 | 2/8 | 0/4 | 1/8 | 1/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 1/5 | 0/8 | 0/2 | 1/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 1/4 | 0/7 |
| Pelvic painReproductive system and breast disorders | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 1/2 | 1/15 | 0/8 | 1/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| Lower respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 2/5 | 0/7 | 0/5 | 2/5 | 0/8 | 0/2 | 0/2 | 0/2 | 0/15 | 1/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 2/7 |
| Event | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg, BD | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 0/4 | 1/8 | 2/4 | 2/8 | 0/8 | 2/6 | 1/6 | 2/6 | 1/4 | 0/5 | 2/7 | 0/5 | 2/5 | 6/8 | 1/2 | 0/2 | 0/2 | 3/15 | 0/8 | 3/7 | 0/7 | 1/9 | 0/2 | 0/3 | 1/6 | 1/5 | 0/4 | 0/1 | 1/1 | 1/6 | 4/16 | 2/20 | 0/4 | 0/4 | 2/7 |
| Abdominal discomfortGastrointestinal disorders | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 1/1 | 0/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| ConstipationGastrointestinal disorders | 4/4 | 1/4 | 3/8 | 1/4 | 2/8 | 2/8 | 1/6 | 1/6 | 1/6 | 2/4 | 0/5 | 4/7 | 0/5 | 2/5 | 1/8 | 0/2 | 0/2 | 0/2 | 6/15 | 3/8 | 5/7 | 3/7 | 0/9 | 0/2 | 2/3 | 0/6 | 3/5 | 1/4 | 1/1 | 1/1 | 1/6 | 3/16 | 3/20 | 1/4 | 0/4 | 5/7 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/4 | 3/8 | 1/4 | 1/8 | 1/8 | 2/6 | 1/6 | 2/6 | 1/4 | 2/5 | 3/7 | 2/5 | 2/5 | 3/8 | 1/2 | 1/2 | 0/2 | 6/15 | 0/8 | 2/7 | 4/7 | 0/9 | 0/2 | 2/3 | 2/6 | 0/5 | 0/4 | 1/1 | 1/1 | 2/6 | 5/16 | 3/20 | 1/4 | 2/4 | 2/7 |
| GastritisGastrointestinal disorders | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 1/1 | 0/1 | 0/6 | 0/16 | 1/20 | 0/4 | 0/4 | 0/7 |
| NauseaGastrointestinal disorders | 3/4 | 0/4 | 4/8 | 0/4 | 6/8 | 4/8 | 2/6 | 2/6 | 2/6 | 1/4 | 0/5 | 3/7 | 4/5 | 2/5 | 0/8 | 1/2 | 1/2 | 1/2 | 3/15 | 2/8 | 4/7 | 3/7 | 3/9 | 0/2 | 1/3 | 2/6 | 2/5 | 4/4 | 0/1 | 1/1 | 3/6 | 5/16 | 3/20 | 1/4 | 2/4 | 5/7 |
| VomitingGastrointestinal disorders | 2/4 | 0/4 | 2/8 | 1/4 | 3/8 | 1/8 | 0/6 | 0/6 | 0/6 | 2/4 | 2/5 | 0/7 | 1/5 | 0/5 | 0/8 | 1/2 | 0/2 | 0/2 | 3/15 | 2/8 | 1/7 | 1/7 | 1/9 | 0/2 | 1/3 | 0/6 | 2/5 | 1/4 | 0/1 | 1/1 | 1/6 | 6/16 | 2/20 | 2/4 | 1/4 | 4/7 |
| FatigueGeneral disorders and administration site conditions | 1/4 | 1/4 | 3/8 | 3/4 | 3/8 | 4/8 | 2/6 | 2/6 | 2/6 | 2/4 | 4/5 | 5/7 | 4/5 | 4/5 | 4/8 | 0/2 | 2/2 | 1/2 | 7/15 | 4/8 | 6/7 | 3/7 | 5/9 | 1/2 | 3/3 | 3/6 | 5/5 | 3/4 | 1/1 | 1/1 | 3/6 | 4/16 | 5/20 | 3/4 | 3/4 | 5/7 |
| Lower respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 0/8 | 0/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 1/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 1/2 | 0/2 | 0/15 | 1/8 | 2/7 | 0/7 | 0/9 | 0/2 | 1/3 | 0/6 | 3/5 | 1/4 | 1/1 | 0/1 | 1/6 | 1/16 | 1/20 | 0/4 | 0/4 | 1/7 |
| MastitisInfections and infestations | 0/4 | 0/4 | 0/8 | 1/4 | 0/8 | 0/8 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/7 | 0/5 | 0/5 | 0/8 | 0/2 | 0/2 | 0/2 | 0/15 | 0/8 | 0/7 | 0/7 | 0/9 | 0/2 | 0/3 | 0/6 | 0/5 | 0/4 | 0/1 | 1/1 | 0/6 | 0/16 | 0/20 | 0/4 | 0/4 | 0/7 |
| Age, Continuous(years) | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 72.0 ± 6.27 | 70.3 ± 10.81 | 67.6 ± 6.44 | 73.8 ± 3.30 | 74.3 ± 6.86 | 69.5 ± 8.75 | 70.7 ± 8.24 | 68.7 ± 9.00 | 70.0 ± 2.83 | 64.8 ± 6.90 | 64.8 ± 3.42 | 71.4 ± 5.77 | 73.4 ± 4.93 | 74.2 ± 6.80 | 75.0 ± 4.24 | 73.5 ± 0.71 | 78.0 ± 1.41 | 71.1 ± 6.41 | 70.0 ± 4.57 | 70.9 ± 7.22 | 66.6 ± 6.00 | 74.0 ± 5.52 | 68.5 ± 3.54 | 68.7 ± 12.06 | 67.7 ± 5.39 | 69.0 ± 9.14 | 60.8 ± 5.19 | 76.0 ± NA | 41.0 ± NA | 56.3 ± 14.84 | 59.7 ± 12.58 | 68.8 ± 4.11 | 70.0 ± 2.71 | 67.3 ± 15.42 | 67.3 ± 15.42 |
| Sex: Female, Male(Participants) | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 24 | 0 | 0 | 4 | 33 |
| Male | 4 | 4 | 8 | 4 | 8 | 8 | 6 | 6 | 6 | 4 | 5 | 7 | 5 | 5 | 2 | 2 | 2 | 23 | 8 | 7 | 7 | 9 | 2 | 3 | 6 | 5 | 4 | 1 | 0 | 2 | 12 | 4 | 4 | 3 | 186 |
| Race (NIH/OMB)(Participants) | Part A: CCS1477 100mg, Once Daily | Part A: CCS1477 100mg, 2/Week | Part A: CCS1477 100mg, 3 Days on and 4 Days Off | Part A: CCS1477 100mg, 3/Week | Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off | Part A: CCS1477 50mg, Once Daily | Part A: CCS1477 25mg BD, Daily | Part A: CCS1477 25 mg, Once Daily | Part A: CCS1477 50mg, 4 Days on and 3 Days Off | Part A: CCS1477 50mg, 5 Days on and 2 Days Off | Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off | Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off | Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off | Part A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off | Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off | Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off | Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily | Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off | Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off | Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off | Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off | Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off | Part E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off | Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off | Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| White | 4 | 4 | 8 | 4 | 8 | 7 | 5 | 6 | 6 | 4 | 5 | 6 | 5 | 5 | 2 | 2 | 2 | 23 | 8 | 7 | 6 | 9 | 2 | 2 | 6 | 5 | 4 | 1 | 1 | 6 | 21 | 3 | 4 | 6 | 197 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 1 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Jul 2025, 83 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 83 months is above that.
Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CCS1477
CellCentric Ltd.